

February 19, 2014

Peregrine Pharmaceuticals Announces Upcoming Events

TUSTIN, CA -- (Marketwired) -- 02/19/14 -- Peregrine Pharmaceuticals, Inc. (NASDAQ: PPHM), a biopharmaceutical company developing first-in-class monoclonal antibodies focused on the treatment and diagnosis of cancer, today announced that the company will participate in the following investor conferences:

2014 RBC Capital Markets' Global Healthcare Conference

Date: Tuesday, February 25, 2014 Time: 2:05 PM Eastern Time

Location: The New York Palace Hotel, New York, New York

Peregrine's presentation at the RBC Capital Market conference will be webcast live and available for replay for 30 days at: http://ir.peregrineinc.com/events.cfm

34th Annual Cowen Health Care Conference
Date: Tuesday, March 4, 2014

Time: 11:20 AM Eastern Time

Location: The Boston Marriott Copley Place, Boston, Massachusetts

This event will not be webcast.

26th Annual ROTH Conference

Date: Monday, March 10, 2014

Time: 1:00 PM Pacific Time (4:00 PM Eastern Time)

Location: The Ritz Carlton Laguna Niguel, Dana Point, California

Peregrine's presentation at the Roth conference will be webcast live and available for replay for 30 days at: http://ir.peregrineinc.com/events.cfm

About Peregrine Pharmaceuticals

Peregrine Pharmaceuticals, Inc. is a biopharmaceutical company with a portfolio of innovative monoclonal antibodies in clinical trials focused on the treatment and diagnosis of cancer. The company is pursuing multiple clinical programs in cancer with its lead immunotherapy candidate bavituximab and novel brain cancer agent Cotara®. Peregrine also has in-house cGMP manufacturing capabilities through its wholly-owned subsidiary Avid Bioservices, Inc. (www.avidbio.com), which provides development and biomanufacturing services for both Peregrine and third-party customers. Additional information about Peregrine can be found at www.peregrineinc.com.

Contact:

Christopher Keenan or Jay Carlson Peregrine Pharmaceuticals (800) 987-8256 info@peregrineinc.com

Source: Peregrine Pharmaceuticals

News Provided by Acquire Media